These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33016804)

  • 1. The efficacy and safety of a homoharringtonine-based protocol for children with acute myeloid leukemia: A retrospective study in China.
    Tang Y; Luo C; Shen S; Xue H; Pan C; Hu W; Chen X; Cai J; Chen J; Tang J
    Pediatr Hematol Oncol; 2021 Mar; 38(2):97-107. PubMed ID: 33016804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia.
    Chen X; Tang Y; Chen J; Chen R; Gu L; Xue H; Pan C; Tang J; Shen S
    Front Med; 2019 Jun; 13(3):378-387. PubMed ID: 30635781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with
    Wang F; Xu W; Liu L; Ren X; Liu P; Zheng L; Zhang H; Zhang S; Xu Y; Guo Z
    Hematology; 2021 Dec; 26(1):1040-1045. PubMed ID: 34895093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.
    Tang J; Liu Y; Chen J; Xue H; Pan C; Gu L
    Int J Hematol; 2011 May; 93(5):610-617. PubMed ID: 21509439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single-arm, phase 2 trial (RJ-AML 2014).
    Zhang Y; Li X; Weng X; Shen Y; Chen Y; Zheng Y; Zhao H; You J; Mao Y; Wang L; Wu M; Sheng Y; Wu J; Hu J; Chen Q; Li J
    Am J Hematol; 2022 Jan; 97(1):43-51. PubMed ID: 34687467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study.
    Li J; Gao J; Liu A; Liu W; Xiong H; Liang C; Fang Y; Dai Y; Shao J; Yu H; Wang L; Wang L; Yang L; Yan M; Zhai X; Shi X; Tian X; Ju X; Chen Y; Wang J; Zhang L; Liang H; Chen S; Zhang J; Cao H; Jin J; Hu Q; Wang J; Wang Y; Zhou M; Han Y; Zhang R; Zhao W; Wang X; Lin L; Zhang R; Gao C; Xu L; Zhang Y; Fan J; Wu Y; Lin W; Yu J; Qi P; Huang P; Peng X; Peng Y; Wang T; Zheng H;
    J Clin Oncol; 2023 Nov; 41(31):4881-4892. PubMed ID: 37531592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].
    Zhang CX; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Wei SN; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):383-387. PubMed ID: 35680595
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial.
    Jin J; Wang JX; Chen FF; Wu DP; Hu J; Zhou JF; Hu JD; Wang JM; Li JY; Huang XJ; Ma J; Ji CY; Xu XP; Yu K; Ren HY; Zhou YH; Tong Y; Lou YJ; Ni WM; Tong HY; Wang HF; Mi YC; Du X; Chen BA; Shen Y; Chen Z; Chen SJ
    Lancet Oncol; 2013 Jun; 14(7):599-608. PubMed ID: 23664707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01.
    De Moerloose B; Reedijk A; de Bock GH; Lammens T; de Haas V; Denys B; Dedeken L; van den Heuvel-Eibrink MM; Te Loo M; Uyttebroeck A; Van Damme A; Van der Werff-Ten Bosch J; Zsiros J; Kaspers G; de Bont E
    Pediatr Blood Cancer; 2019 May; 66(5):e27605. PubMed ID: 30623572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
    Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Homoharringtonine for the Treatment of Acute Myeloid Leukemia: A Meta-analysis.
    Mi R; Zhao J; Chen L; Wei X; Liu J; Wei X
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e752-e767. PubMed ID: 34301487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of venetoclax-based induction regimen in newly diagnosed pediatric acute myeloid leukemia].
    Wen XJ; Lu Y; Huang PL; Zhang YY; Yu JJ; Qi PJ; Huang Q; Yang J; Liu HQ; Hou B; Wang LY; Li HQ; Lin W; Wu Y; Zhang RD; Li J; Luo D; Li YN; Liu M; Zhao ZW; Liu Y; Zheng HY
    Zhonghua Yi Xue Za Zhi; 2024 Jul; 104(27):2513-2520. PubMed ID: 38978375
    [No Abstract]   [Full Text] [Related]  

  • 14. High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.
    Huang BT; Zeng QC; Yu J; Liu XL; Xiao Z; Zhu HQ
    Med Oncol; 2012 Mar; 29(1):251-9. PubMed ID: 21258877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.
    Wang J; Lü S; Yang J; Song X; Chen L; Huang C; Hou J; Zhang W
    J Hematol Oncol; 2009 Jul; 2():32. PubMed ID: 19642997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies.
    Kantarjian H; O'Brien S; Jabbour E; Barnes G; Pathak A; Cortes J
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):13-21. PubMed ID: 25458084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism.
    Wang F; Xie M; Chen P; Wang D; Yang M
    Oxid Med Cell Longev; 2022; 2022():8212286. PubMed ID: 35873796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
    Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
    J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.
    Mi Y; Xue Y; Yu W; Liu S; Zhao Y; Meng Q; Bian S; Wang J
    Leuk Lymphoma; 2008 Mar; 49(3):524-30. PubMed ID: 18297530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A long-term follow-up study of 82 children with acute myeloid leukemia].
    Ruan M; Qi BQ; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
    Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):730-734. PubMed ID: 30293275
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.